Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: An update

Cancer Immunology, Immunotherapy

Volumn 57, Issue 6, 2008, Pages 759-775

  Beachy, S H ^a   Repasky, E A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Monitoring cancer therapy; Treatment efficacy markers; Treatment response markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOCHROME C; CYTOKERATIN 18; DNA; GELATINASE A; INTERLEUKIN 6; IRINOTECAN; LIPID; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UVOMORULIN;

APOPTOSIS; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CULTURE MEDIUM; DRUG EFFICACY; DRUG MONITORING; HUMAN; MACROMOLECULE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; APOPTOSIS; CASPASES; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; LIPIDS; MEDICAL ONCOLOGY; MICE; MODELS, BIOLOGICAL; NEOPLASMS; NUCLEOSOMES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 43349108192     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0445-6     Document Type: Review

References (111)

1. Abraham J, Allegra CJ (2001) (eds) Bethesda Handbook of Clinical Oncology. Lippincott Williams and Wilkins, Philadelphia
2. Ahlemeyer B, Klumpp S, Krieglstein J (2002) Release of cytochrome c into the extracellular space contributes to neuronal apoptosis induced by staurosporine. Brain Res 934:107-116
3. Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14:337-348
4. Aquino A, Prete SP, Guadagni F, Greiner JW, Giuliani A, Orlando L, Masci G, De Santis S, Bonmassar E, Graziani G (2000) Effect of 5-fluorouracil on carcinoembryonic antigen expression and shedding at clonal level in colon cancer cells. Anticancer Res 20:3475-3484
5. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
6. Baker M (2005) In biomarkers we trust? Nat Biotechnol 23:297-304
7. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, Manns MP, Schulze-Osthoff K (2004) Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40:1078-1087
8. Barczyk K, Kreuter M, Pryjma J, Booy EP, Maddika S, Ghavami S, Berdel WE, Roth J, Los M (2005) Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer 116:167-173
9. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(Suppl 3):274-281
10. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A (2002) Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 8:2766-2774
11. Benson AB III, Choti MA, Cohen AM, Doroshow JH, Fuchs C, Kiel K, Martin EW Jr, McGinn C, Petrelli NJ, Posey JA, Skibber JM, Venook A, Yeatman TJ (2000) NCCN practice guidelines for colorectal cancer. Oncol (Williston Park) 14:203-212
12. Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, Rowley B, Wood J, Zhang C, Toi M, Shoshan MC, Linder S (2003) A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8:263-268
13. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2:241-243
14. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93:691-699
15. Cantarella G, Risuglia N, Dell'eva R, Lempereur L, Albini A, Pennisi G, Scoto GM, Noonan DN, Bernardini R (2006) TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer 94:1428-1435
16. Chabre H, Amoura Z, Piette JC, Godeau P, Bach JF, Koutouzov S (1995) Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 38:1485-1491
17. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791
18. Diamandis EP (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96:353-356
19. Diamandis EP (2006) Peptidomics for cancer diagnosis: present and future. J Proteome Res 5:2079-2082
20. Dickson PV, Hamner JB, Cauthen LA, Ng CY, McCarville MB, Davidoff AM (2006) Efficacy of zoledronate against neuroblastoma. Surgery 140:227-235
21. Espina V, Dettloff KA, Cowherd S, Petricoin EF III, Liotta LA (2004) Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 4:83-93
22. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L (2003) The case for early detection. Nat Rev Cancer 3:243-252
23. Feldstein AE, Gores GJ (2004) An apoptosis biomarker goes to the HCV clinic. Hepatology 40:1044-1046
24. Feneley MR, Partin AW (2000) Diagnosis of localized prostate cancer: 10 years of progress. Curr Opin Urol 10:319-327
25. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M (2005) Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65:1141-1145
26. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605-613
27. Gee MS, Upadhyay R, Bergquist H, Weissleder R, Josephson L, Mahmood U (2007) Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment. Int J Cancer 121:2492-2500
28. Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA, O'Byrne K, Hollywood D, Muldoon C, Reynolds JV (2006) (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 95:1174-1179
29. Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657-663
30. Green DR (2000) Apoptotic pathways: paper wraps stone blunts scissors. Cell 102:1-4
31. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
32. Hanke B, Wein A, Martus P, Riedel C, Voelker M, Hahn EG, Schuppan D (2003) Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br J Cancer 88:1248-1250
33. Hannun YA (1997) Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845-1853
34. Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, Rinehart JJ, Crawford ED, Bonnet JD, Behrens BC (1991) Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother 10:426-431
35. Hohlbaum AM, Gregory MS, Ju ST, Marshak-Rothstein A (2001) Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 167:6217-6224
36. Holdenrieder S, Holubec L Jr, Topolcan O, Finek J, Stieber P (2005) Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res 25:1795-1801
37. Holdenrieder S, Stieber P (2004) Apoptotic markers in cancer. Clin Biochem 37:605-617
38. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D (2004) Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 10:5981-5987
39. Huntly BJ, Gilliland DG (2005) Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5:311-321
40. Jaffe CC (2006) Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245-3251
41. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659-1665
42. Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42-49
43. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
44. Kim R, Emi M, Tanabe K (2006) The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther 5:1429-1442
45. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611-620
46. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64:1751-1756
47. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S (2006) Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94:1592-1598
48. Kremer A, Holdenrieder S, Stieber P, Wilkowski R, Nagel D, Seidel D (2006) Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol 27:235-242
49. Kremer A, Wilkowski R, Holdenrieder S, Nagel D, Stieber P, Seidel D (2005) Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol 26:44-49
50. Lee KC, Sud S, Meyer CR, Moffat BA, Chenevert TL, Rehemtulla A, Pienta KJ, Ross BD (2007) An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 67:3524-3529
51. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567-572
52. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-650
53. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO (2005) Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65:4202-4210
54. Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501
55. Linder S, Havelka AM, Ueno T, Shoshan MC (2004) Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 214:1-9
56. Liotta LA, Petricoin EF (2006) Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116:26-30
57. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327
58. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490
59. Meggiato T, Calabrese F, Valente M, Favaretto E, Baliello E, Del Favero G (2000) Spontaneous apoptosis and proliferation in human pancreatic cancer. Pancreas 20:117-122
60. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF III, Liotta LA (2003) Biomarker amplification by serum carrier protein binding. Dis Markers 19:1-10
61. Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, Gulley J, Petricoin E, Coleman CN, Whiteley G, Liotta L, Camphausen K (2006) Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 66:1844-1850
62. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C (1993) An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270:943-947
63. Mueller S, Holdenrieder S, Stieber P, Haferlach T, Schalhorn A, Braess J, Nagel D, Seidel D (2006) Early prediction of therapy response in patients with acute myeloid leukaemia by nucleosomal DNA fragments. BMC Cancer 6:143
64. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA (2002) Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62:5800-5806
65. Neves AA, Brindle KM (2006) Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta 1766:242-261
66. Neves AA, Krishnan AS, Kettunen MI, Hu DE, Backer MM, Davletov B, Brindle KM (2007) A paramagnetic nanoprobe to detect tumor cell death using magnetic resonance imaging. Nano Lett 7:1419-1423
67. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806-809
68. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13:3198-3206
69. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ (2007) Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 25:146-162
70. Pardo J, Bosque A, Brehm R, Wallich R, Naval J, Mullbacher A, Anel A, Simon MM (2004) Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. J Cell Biol 167:457-468
71. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577
72. Petricoin EF, Belluco C, Araujo RP, Liotta LA (2006) The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 6:961-967
73. Pichon MF, Labroquere M, Rezai K, Lokiec F (2006) Variations of soluble fas and cytokeratin 18-Asp 396 neo-epitope in different cancers during chemotherapy. Anticancer Res 26:2387-2392
74. Platoshyn O, Zhang S, McDaniel SS, Yuan JX (2002) Cytochrome c activates K+ channels before inducing apoptosis. Am J Physiol Cell Physiol 283:C1298-C1305
75. Radic M, Marion T, Monestier M (2004) Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 172:6692-6700
76. Rantalainen M, Cloarec O, Beckonert O, Wilson ID, Jackson D, Tonge R, Rowlinson R, Rayner S, Nickson J, Wilkinson RW, Mills JD, Trygg J, Nicholson JK, Holmes E (2006) Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. J Proteome Res 5:2642-2655
77. Rathmell JC, Thompson CB (2002) Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 109(Suppl):S97-S107
78. Renz A, Berdel WE, Kreuter M, Belka C, Schulze-Osthoff K, Los M (2001) Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood 98:1542-1548
79. Sayar D, Yaniv I, Goshen Y, Cohen IJ (2001) Treatment of alpha-fetoprotein secreting hepatoblastoma by response of serum alpha-fetoprotein levels: a new concept. Pediatr Hematol Oncol 18:509-518
80. Screpanti V, Wallin RP, Grandien A, Ljunggren HG (2005) Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 42:495-499
81. Sellins KS, Cohen JJ (1987) Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 139:3199-3206
82. Serrano M (2007) Cancer regression by senescence. N Engl J Med 356:1996-1997
83. Sheard MA, Vojtesek B, Simickova M, Valik D (2002) Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 85:670-677
84. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263:8350-8358
85. Skladanowski A, Konopa J (1993) Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 46:375-382
86. Smalley M, Ashworth A (2003) Stem cells and breast cancer: a field in transit. Nat Rev Cancer 3:832-844
87. Sorace JM, Zhan M (2003) A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinf 4:24
88. Sorbye H, Dahl O (2003) Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol 21:4466-4467
89. Sorbye H, Dahl O (2004) Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 43:495-498
90. Stefflova K, Chen J, Li H, Zheng G (2006) Targeted photodynamic therapy agent with a built-in apoptosis sensor for in vivo near-infrared imaging of tumor apoptosis triggered by its photosensitization in situ. Mol Imaging 5:520-532
91. Steinhusen U, Weiske J, Badock V, Tauber R, Bommert K, Huber O (2001) Cleavage and shedding of E-cadherin after induction of apoptosis. J Biol Chem 276:4972-4980
92. Strater J, Koretz K, Gunthert AR, Moller P (1995) In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis. Gut 37:819-825
93. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W (2006) Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12:5659-5667
94. Trejo-Becerril C, Perez-Cardenas E, Trevino-Cuevas H, Taja-Chayeb L, Garcia-Lopez P, Segura-Pacheco B, Chavez-Blanco A, Lizano-Soberon M, Gonzalez-Fierro A, Mariscal I, Wegman-Ostrosky T, Duenas-Gonzalez A (2003) Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int J Cancer 104:663-668
95. Uchimura E, Kodaira T, Kurosaka K, Yang D, Watanabe N, Kobayashi Y (1997) Interaction of phagocytes with apoptotic cells leads to production of pro-inflammatory cytokines. Biochem Biophys Res Commun 239:799-803
96. Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S (2003) Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39:769-774
97. Van de Wiele C, Lahorte C, Oyen W, Boerman O, Goethals I, Slegers G, Dierckx RA (2003) Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 55:5-15
98. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661-665
99. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39-51
100. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A (2005) Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 173:1456-1462
101. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284
102. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
103. Weinberg RA (2007) (eds) The biology of cancer. Garland Science, Taylor and Francis Group, LLC, New York
104. Wells MJ, Hatton MW, Hewlett B, Podor TJ, Sheffield WP, Blajchman MA (1997) Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes. J Biol Chem 272:28574-28581
105. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W (2001) Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 51:56-61
106. Wickremesekera JK, Chen W, Cannan RJ, Stubbs RS (2001) Serum proinflammatory cytokine response in patients with advanced liver tumors following selective internal radiation therapy (SIRT) with (90)Yttrium microspheres. Int J Radiat Oncol Biol Phys 49:1015-1021
107. Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555-556
108. Yamauchi K, Yang M, Jiang P, Xu M, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM (2006) Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res 66:4208-4214
109. Yu J, Yue W, Wu B, Zhang L (2006) PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 12:2928-2936
110. Zhang J, Driscoll TA, Hannun YA, Obeid LM (1998) Regulation of membrane release in apoptosis. Biochem J 334(Pt 2):479-485
111. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413